BioLife Solutions Inc
BLFS
13.68USD-0.18 (-1.30%)Delayed as of 05 Dec 2023, 10:02 amWatchlist
Market Summary
USD13.68-0.18
Delayedas of 05 Dec 2023, 10:02 am-1.30%
BLFS Stock Price
View Fullscreen
BLFS RSI Chart
BLFS Valuation
BLFS Price/Sales (Trailing)
BLFS Profitability
BLFS Fundamentals
BLFS Revenue
BLFS Earnings
Price Action
52 Week Range
10.4826.89
(Low)(High)
Last 7 days
2.9%
Last 30 days
21.1%
Last 90 days
6.4%
Trailing 12 Months
-36.9%
How does BLFS drawdown profile look like?
BLFS Financial Health
BLFS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 163.2M | 162.2M | 154.8M | 0 |
| 2022 | 138.5M | 147.9M | 154.8M | 161.8M |
| 2021 | 52.8M | 74.1M | 96.6M | 119.2M |
| 2020 | 33.8M | 37.0M | 41.7M | 48.1M |
| 2019 | 21.7M | 23.2M | 24.5M | 27.4M |
| 2018 | 12.5M | 15.1M | 17.4M | 19.7M |
| 2017 | 8.7M | 9.3M | 10.1M | 11.0M |
| 2016 | 6.8M | 7.3M | 7.8M | 8.2M |
| 2015 | 5.6M | 5.9M | 6.3M | 6.4M |
| 2014 | 9.6M | 8.5M | 7.6M | 6.2M |
| 2013 | 5.4M | 6.7M | 7.2M | 8.2M |
| 2012 | 3.0M | 3.5M | 4.4M | 5.7M |
| 2011 | 2.3M | 2.4M | 2.6M | 2.8M |
| 2010 | 0 | 0 | 0 | 2.1M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BLFS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Nov 13, 2023 | berard todd | sold | -1,055 | 10.77 | -98.00 | chief marketing officer |
| Nov 13, 2023 | foster karen a. | sold | -1,227 | 10.77 | -114 | chief quality officer |
| Nov 13, 2023 | phillips geraint | sold | -1,183 | 10.66 | -111 | svp, global operations |
| Nov 13, 2023 | wichterman troy | sold | -1,034 | 10.66 | -97.00 | chief financial officer |
| Nov 13, 2023 | aebersold sarah | sold | -818 | 10.77 | -76.00 | chief human resources officer |
| Nov 13, 2023 | mathew aby j. | sold | -1,421 | 10.77 | -132 | evp & chief scientific officer |
| Nov 05, 2023 | mathew aby j. | acquired | - | - | 924 | evp & chief scientific officer |
| Nov 05, 2023 | foster karen a. | acquired | - | - | 299 | chief quality officer |
| Nov 05, 2023 | phillips geraint | acquired | - | - | 262 | svp, global operations |
| Nov 05, 2023 | wichterman troy | acquired | - | - | 333 | chief financial officer |
Which funds bought or sold BLFS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -73.73 | -1,396,590 | 274,349 | -% |
| Nov 22, 2023 | Public Sector Pension Investment Board | reduced | -31.18 | -777,305 | 586,442 | -% |
| Nov 22, 2023 | KBC Group NV | unchanged | - | - | 57,000 | -% |
| Nov 21, 2023 | COMERICA BANK | new | - | 258,722 | 258,722 | -% |
| Nov 21, 2023 | Spears Abacus Advisors LLC | reduced | -5.03 | -258,793 | 377,731 | 0.03% |
| Nov 15, 2023 | MORGAN STANLEY | reduced | -3.24 | -3,426,670 | 5,240,770 | -% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | new | - | 1,035,050 | 1,035,050 | 0.01% |
| Nov 15, 2023 | CAPTRUST FINANCIAL ADVISORS | sold off | -100 | -222,304 | - | -% |
| Nov 15, 2023 | Baker Avenue Asset Management, LP | unchanged | - | -4,924 | 8,203 | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | added | 2.14 | -110,613 | 195,163 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of BioLife Solutions Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Oct 24, 2023 | casdin capital, llc | 19.5% | 8,707,165 | SC 13D/A | |
| Sep 26, 2023 | integrated core strategies (us) llc | 5.5% | 2,406,913 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 5.77% | 2,466,931 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 12.8% | 5,477,126 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 12.8% | 5,477,126 | SC 13G/A | |
| Jan 11, 2023 | millennium management llc | 1.6% | 670,202 | SC 13G/A | |
| Jul 08, 2022 | blackrock inc. | 11.5% | 4,893,203 | SC 13G | |
| Jun 22, 2022 | millennium management llc | 5.1% | 2,166,344 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 5.16% | 2,147,258 | SC 13G | |
| Feb 01, 2022 | blackrock inc. | 8.8% | 3,655,057 | SC 13G/A |
Recent SEC filings of BioLife Solutions Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Dec 04, 2023 | 4 | Insider Trading | |
| Dec 04, 2023 | 4 | Insider Trading | |
| Dec 04, 2023 | 4 | Insider Trading | |
| Dec 04, 2023 | 4 | Insider Trading | |
| Dec 04, 2023 | 4 | Insider Trading | |
| Dec 04, 2023 | 4 | Insider Trading | |
| Nov 30, 2023 | S-3/A | S-3/A | |
| Nov 17, 2023 | S-3 | S-3 | |
| Nov 17, 2023 | S-3 | S-3 | |
| Nov 15, 2023 | 4 | Insider Trading |
BLFS Fair Value
Loading...
Peers (Alternatives to BioLife Solutions Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABT | 183.0B | 40.0B | 9.73% | -2.70% | 35.46 | 4.58 | -11.26% | -34.57% |
BDX | 71.3B | 19.4B | -8.25% | -5.16% | 44.09 | 3.79 | 2.66% | -16.58% |
BAX | 18.7B | 15.0B | 8.63% | -30.19% | 7.2 | 1.24 | 3.01% | 209.09% |
ALGN | 16.8B | 3.8B | 11.22% | 10.68% | 46.36 | 4.42 | -1.48% | -28.97% |
| MID-CAP | ||||||||
HSIC | 9.0B | 12.7B | 11.09% | -16.77% | 20.24 | 0.71 | 0.68% | -30.25% |
BIO | 9.0B | 2.7B | 7.31% | -26.28% | -56.42 | 3.3 | -3.01% | 97.36% |
ATR | 8.4B | 3.4B | 2.45% | 18.85% | 30.02 | 2.45 | 3.13% | 18.17% |
XRAY | 6.9B | 3.9B | 12.08% | 3.35% | -31.81 | 1.76 | -2.62% | 73.28% |
AXNX | 2.9B | 342.6M | 6.85% | -17.46% | -245.59 | 8.59 | 42.19% | 84.14% |
PDCO | 2.5B | 6.6B | -16.25% | -11.02% | 12.27 | 0.37 | 2.61% | 0.62% |
| SMALL-CAP | ||||||||
AHCO | 1.2B | 3.1B | 8.50% | -59.80% | -2.91 | 0.4 | 7.95% | -550.16% |
ANIK | 333.0M | 163.3M | 7.72% | -27.92% | -13.55 | 2.04 | 7.14% | -56.09% |
ANGO | 272.3M | 335.9M | -0.73% | -44.59% | 42.24 | 0.81 | 4.71% | 116.39% |
APYX | 74.8M | 50.3M | -17.56% | 18.68% | -4.94 | 1.49 | 3.23% | 20.81% |
AEMD | 5.1M | 3.8M | 9.63% | -51.71% | -0.44 | 1.35 | 17.30% | 10.67% |
BioLife Solutions Inc News
Latest updates
Financials for BioLife Solutions Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | -15.6% | 33,328,000 | 39,508,000 | 37,703,000 | 44,259,000 | 40,747,000 | 40,533,000 | 36,220,000 | 37,305,000 | 33,800,000 | 31,204,000 | 16,847,000 | 14,726,000 | 11,279,000 | 9,920,000 | 12,162,000 | 8,296,000 | 6,604,000 | 6,701,000 | 5,770,000 | 5,456,000 | 5,293,000 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4,520,000 | 4,743,000 | 4,123,000 | 3,746,000 | 3,687,000 |
| Costs and Expenses | 13.4% | 62,111,000 | 54,788,000 | 51,308,000 | 94,182,500 | 52,152,000 | 117,096,000 | 44,187,000 | 55,770,000 | 44,959,000 | 35,759,000 | 17,828,000 | 20,135,000 | 12,525,000 | 9,876,000 | 11,792,000 | 9,057,000 | 7,376,000 | 5,954,000 | 5,204,000 | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7,376,000 | 5,954,000 | 5,204,000 | -1,803,500 | 4,098,000 |
| S&GA Expenses | 14.8% | 7,256,000 | 6,318,000 | 6,471,000 | 5,987,000 | 5,277,000 | 5,415,000 | 4,891,000 | 4,778,000 | 4,065,000 | 3,142,000 | 2,021,000 | 1,883,000 | 1,588,000 | 1,366,000 | 1,576,000 | 1,669,000 | 1,250,000 | 945,000 | 837,000 | 637,000 | 725,000 |
| R&D Expenses | 11.6% | 5,402,000 | 4,840,000 | 4,152,000 | 4,164,000 | 3,425,000 | 3,428,000 | 3,781,000 | 3,570,500 | 3,219,000 | 3,045,000 | 1,987,000 | 1,855,000 | 1,725,000 | 1,477,000 | 1,663,000 | 1,086,000 | 1,032,000 | 691,000 | 359,000 | 315,000 | 312,000 |
| EBITDA Margin | 100.0% | - | -0.47 | -0.88 | -0.85 | -0.67 | -0.67 | -0.21 | -0.19 | -0.13 | -0.13 | -0.41 | 0.03 | 0.19 | 0.52 | 1.16 | -0.09 | - | - | - | - | - |
| Interest Expenses | 4.8% | 459,000 | 438,000 | 497,000 | 356,000 | 109,000 | 30,000 | 91,000 | 452,000 | - | - | - | -4,000 | 3,000 | - | 1,000 | -5,000 | 1,000 | 1,000 | 3,000 | 1,500 | 1,000 |
| Income Taxes | 2200.0% | 115,000 | 5,000 | 92,000 | 45,997,446,500 | -599,000 | -3,739,000 | -599,000 | -2,578,000 | -4,988,000 | -12,552,000 | - | -3,264,000 | - | - | - | -1,541,000 | - | - | - | - | - |
| Earnings Before Taxes | -184.6% | -29,017,000 | -10,194,000 | -13,622,000 | -49,973,500 | -10,556,000 | -76,617,000 | -8,020,000 | -18,323,000 | -4,909,000 | -4,676,000 | -1,118,000 | -6,076,000 | -1,133,000 | -16,380,000 | 22,308,000 | 1,442,000 | 10,269,000 | 4,252,000 | -19,161,000 | -27,378,000 | 1,231,000 |
| EBT Margin | 100.0% | - | -0.52 | -0.92 | -0.90 | -0.72 | -0.72 | -0.25 | -0.23 | -0.17 | -0.17 | -0.46 | -0.01 | 0.15 | 0.48 | 1.13 | -0.12 | - | - | - | - | - |
| Net Income | -185.6% | -29,132,000 | -10,199,000 | -13,714,000 | -49,888,500 | -9,957,000 | -72,878,000 | -7,421,000 | -15,745,000 | 79,000 | 7,876,000 | -1,118,000 | -2,812,000 | -1,133,000 | -16,380,000 | 22,308,000 | 2,983,000 | 10,269,000 | 4,252,000 | -19,161,000 | 20,933,000 | -24,465,000 |
| Net Income Margin | 100.0% | - | -0.52 | -0.90 | -0.86 | -0.67 | -0.64 | -0.10 | -0.06 | 0.05 | 0.05 | -0.39 | 0.06 | 0.19 | 0.49 | 1.05 | -0.06 | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -8,327,000 | -6,007,000 | 3,409,000 | -950,000 | -11,952,000 | -9,380,000 | -2,340,000 | -329,000 | -10,409,000 | 100,000 | 666,000 | -621,000 | 4,098,000 | 541,000 | -1,322,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -5.1% | 411 | 433 | 446 | 450 | 488 | 471 | 544 | 554 | 559 | 521 | 240 | 235 | 196 | 114 | 95.00 | 93.00 | 84.00 | 51.00 | 48.00 | 45.00 | 46.00 |
| Current Assets | -2.9% | 117 | 120 | 133 | 138 | 136 | 118 | 119 | 126 | 131 | 127 | 117 | 115 | 128 | 46.00 | 26.00 | 24.00 | 32.00 | 29.00 | 39.00 | 38.00 | 38.00 |
| Cash Equivalents | -10.0% | 19.00 | 21.00 | 19.00 | 19.00 | 27.00 | 24.00 | 59.00 | 70.00 | 75.00 | 76.00 | 89.00 | 90.00 | 94.00 | 30.00 | 6.00 | 6.00 | 21.00 | 20.00 | 32.00 | 31.00 | 32.00 |
| Inventory | 10.7% | 43.00 | 39.00 | 41.00 | 35.00 | 34.00 | 33.00 | 30.00 | 28.00 | 30.00 | 26.00 | 12.00 | 12.00 | 11.00 | 11.00 | 11.00 | 11.00 | 6.00 | 5.00 | 4.00 | 4.00 | 3.00 |
| Net PPE | -17.9% | 21.00 | 26.00 | 26.00 | 24.00 | 22.00 | 19.00 | 18.00 | 18.00 | 17.00 | 16.00 | 11.00 | 10.00 | 5.00 | 5.00 | 5.00 | 6.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Goodwill | 0% | 225 | 225 | 225 | 225 | 225 | 225 | 225 | 225 | 224 | 196 | 58.00 | 58.00 | 25.00 | 34.00 | 34.00 | 34.00 | 28.00 | 10.00 | 10.00 | - | - |
| Liabilities | -2.4% | 79.00 | 81.00 | 88.00 | 86.00 | 79.00 | 61.00 | 68.00 | 76.00 | 70.00 | 69.00 | 31.00 | 30.00 | 9.00 | 8.00 | 27.00 | 49.00 | 49.00 | 49.00 | 52.00 | 31.00 | 53.00 |
| Current Liabilities | 7.7% | 43.00 | 40.00 | 47.00 | 45.00 | 37.00 | 36.00 | 38.00 | 43.00 | 36.00 | 31.00 | 16.00 | 16.00 | 8.00 | 7.00 | 25.00 | 8.00 | 5.00 | 3.00 | 3.00 | 2.00 | 2.00 |
| LT Debt, Current | 160.2% | 5.00 | 2.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 2.00 | 3.00 | - | 1.00 | - | - | - | - | - | - | - | - | - |
| LT Debt, Non Current | -11.2% | 21.00 | 24.00 | 24.00 | 24.00 | 24.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | - | 1.00 | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | -5.7% | 332 | 352 | 358 | 364 | 408 | 410 | 476 | 478 | 489 | 452 | 209 | 204 | 187 | 106 | 68.00 | 43.00 | 35.00 | 2.00 | 44.00 | 15.00 | 44.00 |
| Retained Earnings | -10.8% | -299 | -270 | -260 | -246 | -194 | -187 | -114 | -107 | -90.55 | -90.63 | -98.50 | -97.38 | -95.26 | -94.12 | -77.74 | 100 | -103 | -113 | -117 | -98.39 | -119 |
| Additional Paid-In Capital | 1.5% | 633 | 623 | 619 | 612 | 604 | 598 | 591 | 585 | 580 | 543 | 307 | 303 | 282 | 200 | 145 | 143 | 138 | 115 | 114 | 113 | 113 |
| Accumulated Depreciation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Shares Outstanding | 0.9% | 44.00 | 43.00 | 43.00 | 43.00 | 43.00 | 42.00 | 42.00 | 42.00 | 41.00 | 38.00 | 33.00 | 33.00 | 32.00 | 23.00 | 21.00 | 19.00 | 20.00 | 19.00 | 19.00 | 19.00 | 18.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 43.3% | -4,379 | -7,718 | -2,712 | 7,857 | 1,496 | -9,917 | -7,924 | -774 | 2,083 | -7,722 | 1,820 | 2,257 | -502 | 4,203 | 687 | -1,003 | 1,137 | -67.00 | 1,146 | 585 | 808 |
| Share Based Compensation | 33.0% | 9,117 | 6,857 | 7,363 | 7,663 | 6,299 | 5,973 | 5,399 | 5,065 | 4,867 | 2,519 | 1,505 | 2,163 | 1,560 | 1,145 | 1,113 | 864 | 830 | 818 | 531 | 388 | 383 |
| Cashflow From Investing | -82.1% | 1,662 | 9,292 | 2,926 | -14,894 | -15,883 | -25,070 | -2,270 | -2,542 | -2,007 | -4,216 | -4,427 | -22,057 | -975 | -456 | -1,227 | -14,021 | -292 | -12,549 | -156 | -161 | -5,278 |
| Cashflow From Financing | -13.6% | 608 | 704 | -562 | -625 | 17,411 | -289 | -181 | -2,105 | -1,058 | -831 | 1,216 | 1,272 | 80,582 | 19,732 | 492 | 267 | 743 | 409 | 177 | -2,148 | 22,683 |
BLFS Income Statement
2023-09-30Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Total product, rental, and service revenue | $ 33,328 | $ 40,747 | $ 110,538 | $ 117,500 |
| Costs and operating expenses: | ||||
| General and administrative | 12,513 | 11,916 | 42,757 | 35,098 |
| Sales and marketing | 7,256 | 5,278 | 20,045 | 15,601 |
| Research and development | 5,402 | 3,425 | 14,397 | 10,634 |
| Asset impairment charges | 15,485 | 0 | 15,485 | 69,900 |
| Intangible asset amortization | 1,356 | 2,513 | 4,266 | 8,236 |
| Change in fair value of contingent consideration | (1,580) | 2,346 | (1,778) | (3,348) |
| Total operating expenses | 62,111 | 52,487 | 168,208 | 213,770 |
| Operating loss | (28,783) | (11,740) | (57,670) | (96,270) |
| Other (expense) income: | ||||
| Change in fair value of investments | 0 | 697 | 0 | 697 |
| Gain on settlement of Global Cooling escrow | 0 | 0 | 5,115 | 0 |
| Interest expense, net | (476) | (15) | (1,305) | (250) |
| Other income | 242 | 142 | 1,027 | 270 |
| Total other (expense) income, net | (234) | 824 | 4,837 | 717 |
| Loss before income tax (expense) benefit | (29,017) | (10,916) | (52,833) | (95,553) |
| Income tax (expense) benefit | (115) | 599 | (212) | 4,937 |
| Net loss | (29,132) | (10,317) | (53,045) | (90,616) |
| Net loss attributable to common shareholders: | ||||
| Net loss attributable to common shareholders, basic | (29,132) | (10,317) | (53,045) | (90,616) |
| Net loss attributable to common shareholders, diluted | $ (29,132) | $ (10,317) | $ (53,045) | $ (90,616) |
| Net loss per share attributable to common shareholders: | ||||
| Net loss per share attributable to common shareholders, basic (in dollars per share) | $ (0.67) | $ (0.24) | $ (1.22) | $ (2.14) |
| Net loss per share attributable to common shareholders, diluted (in dollars per share) | $ (0.67) | $ (0.24) | $ (1.22) | $ (2.14) |
| Weighted average shares used to compute loss per share attributable to common shareholders: | ||||
| Weighted average shares used to compute loss per share attributable to common shareholders, basic (in shares) | 43,570,438 | 42,647,967 | 43,348,412 | 42,376,392 |
| Weighted average shares used to compute loss per share attributable to common shareholders, diluted (in shares) | 43,570,438 | 42,647,967 | 43,348,412 | 42,376,392 |
| Product revenue | ||||
| Total product, rental, and service revenue | $ 26,891 | $ 33,668 | $ 91,520 | $ 98,227 |
| Costs and operating expenses: | ||||
| Cost of goods and services sold (exclusive of intangible assets amortization) | 16,665 | 21,876 | 57,022 | 63,377 |
| Service revenue | ||||
| Total product, rental, and service revenue | 4,378 | 4,330 | 13,043 | 11,117 |
| Costs and operating expenses: | ||||
| Cost of goods and services sold (exclusive of intangible assets amortization) | 3,945 | 3,253 | 11,873 | 8,810 |
| Rental revenue | ||||
| Total product, rental, and service revenue | 2,059 | 2,749 | 5,975 | 8,156 |
| Costs and operating expenses: | ||||
| Cost of goods and services sold (exclusive of intangible assets amortization) | $ 1,069 | $ 1,880 | $ 4,141 | $ 5,462 |
BLFS Balance Sheet
2023-09-30Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 19,235 | $ 19,442 |
| Restricted cash | 31 | 31 |
| Available-for-sale securities, current portion | 21,794 | 43,260 |
| Accounts receivable, trade, net of allowance for credit losses of $1,244 and $739 as of September 30, 2023 and December 31, 2022, respectively | 24,556 | 33,936 |
| Inventories | 43,354 | 34,904 |
| Prepaid expenses and other current assets | 7,854 | 6,879 |
| Total current assets | 116,824 | 138,452 |
| Assets held for rent, net | 7,209 | 9,064 |
| Property and equipment, net | 20,998 | 23,638 |
| Operating lease right-of-use assets, net | 12,651 | 15,292 |
| Financing lease right-of-use assets, net | 124 | 272 |
| Long-term deposits and other assets | 316 | 281 |
| Available-for-sale securities, long-term | 1,156 | 1,332 |
| Equity investments | 5,069 | 5,069 |
| Intangible assets, net | 22,064 | 32,088 |
| Goodwill | 224,741 | 224,741 |
| Total assets | 411,152 | 450,229 |
| Current liabilities: | ||
| Accounts payable | 11,980 | 15,367 |
| Accrued expenses and other current liabilities | 8,568 | 9,782 |
| Sales taxes payable | 5,469 | 4,151 |
| Warranty liability | 8,215 | 8,312 |
| Lease liabilities, operating, current portion | 2,906 | 2,860 |
| Lease liabilities, financing, current portion | 398 | 158 |
| Debt, current portion | 5,034 | 1,814 |
| Contingent consideration, current portion | 52 | 2,138 |
| Total current liabilities | 42,622 | 44,582 |
| Contingent consideration, long-term | 363 | 2,318 |
| Lease liabilities, operating, long-term | 13,677 | 14,962 |
| Lease liabilities, financing, long-term | 1,250 | 126 |
| Debt, long-term | 20,937 | 23,793 |
| Deferred tax liabilities | 286 | 250 |
| Other long-term liabilities | 0 | 10 |
| Total liabilities | 79,135 | 86,041 |
| Commitments and contingencies (Note 13) | ||
| Shareholders’ equity: | ||
| Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of September 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.001 par value; 150,000,000 shares authorized, 43,831,351 and 42,832,231 shares issued and outstanding, respectively, as of September 30, 2023 and December 31, 2022 | 44 | 43 |
| Additional paid-in capital | 632,593 | 611,739 |
| Accumulated other comprehensive loss, net of taxes | (660) | (679) |
| Accumulated deficit | (299,960) | (246,915) |
| Total shareholders’ equity | 332,017 | 364,188 |
| Total liabilities and shareholders’ equity | $ 411,152 | $ 450,229 |
| CEO | Mr. Michael P. Rice |
|---|---|
| WEBSITE | www.biolifesolutions.com |
| EMPLOYEES | 466 |